Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma Patients Without Metastasis: a Double-blind Randomized Clinical Trial

NCT04354324 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT04354324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04354324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma Patients Without Metastasis: a Double-blind Randomized Clinical Trial
Lead sponsor
Zhujiang Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
April 20, 2020
Completion date
June 30, 2024
Enrollment
254 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

papillary thyroid cancer